ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years
Ling Peng
Matched on ORCID iD 0000-0003-3990-5248; OpenAlex author ID A5002659900. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 16
2012: 2 papers · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 6
- Correction to "Novel Triazole Ribonucleoside Down-Regulates Heat Shock Protein 27 and Induces Potent Anticancer Activity on Drug-Resistant Pancreatic Cancer". Last author DOI 10.1021/acs.jmedchem.5c02592↗
- Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer. Co-author DOI 10.1002/exp.20210003↗
- Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cells8111453↗
- E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based t… Co-author DOI 10.1038/s41598-018-26613-z↗
- Targeting heat shock factor 1 with a triazole nucleoside analog to elicit potent anticancer activity on drug-resistant pancreatic cancer. Last author DOI 10.1016/j.canlet.2011.09.043↗
- Targeting heat shock response pathways to treat pancreatic cancer. Last author DOI 10.1016/j.drudis.2011.09.016↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Juan Iovanna · 6 shared papers, 2012–2025 · strength 0.62
- Paper Correction to "Novel Triazole Ribonucleoside Down-Regulates Heat Shock Protein 27 and Induces Potent Anticancer Activit… DOI 10.1021/acs.jmedchem.5c02592↗
- Paper Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer. DOI 10.1002/exp.20210003↗
- Paper Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. DOI 10.3390/cells8111453↗
- Yi Xia · 5 shared papers, 2012–2025 · strength 0.51
- Paper Correction to "Novel Triazole Ribonucleoside Down-Regulates Heat Shock Protein 27 and Induces Potent Anticancer Activit… DOI 10.1021/acs.jmedchem.5c02592↗
- Paper Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. DOI 10.3390/cells8111453↗
- Paper E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but n… DOI 10.1038/s41598-018-26613-z↗
- Palma Rocchi · 3 shared papers, 2012–2025 · strength 0.34
- Paper Correction to "Novel Triazole Ribonucleoside Down-Regulates Heat Shock Protein 27 and Induces Potent Anticancer Activit… DOI 10.1021/acs.jmedchem.5c02592↗
- Paper Targeting heat shock response pathways to treat pancreatic cancer. DOI 10.1016/j.drudis.2011.09.016↗
- Paper Targeting heat shock factor 1 with a triazole nucleoside analog to elicit potent anticancer activity on drug-resistant … DOI 10.1016/j.canlet.2011.09.043↗
- Odile Gayet · 2 shared papers, 2018–2021 · strength 0.19
- Paper Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer. DOI 10.1002/exp.20210003↗
- Paper E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but n… DOI 10.1038/s41598-018-26613-z↗
- Nelson Dusetti · 2 shared papers, 2018–2021 · strength 0.19
- Paper Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer. DOI 10.1002/exp.20210003↗
- Paper E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but n… DOI 10.1038/s41598-018-26613-z↗
- Wenjun Lan · 2 shared papers, 2018–2019 · strength 0.16
- Patricia Santofimia‐Castaño · 2 shared papers, 2018–2019 · strength 0.16
- Céline Loncle · 1 shared paper, 2021 · strength 0.11
- Xing‐Jie Liang · 1 shared paper, 2021 · strength 0.11
- Juan Liu · 1 shared paper, 2021 · strength 0.11
- Olga Abián · 1 shared paper, 2019 · strength 0.09
- José L. Neira · 1 shared paper, 2019 · strength 0.09
- Philippe Soubeyran · 1 shared paper, 2019 · strength 0.09
- Raul A. Urrutia · 1 shared paper, 2019 · strength 0.09
- Gwen Alyce Lomberk · 1 shared paper, 2019 · strength 0.09
- Benjamin Bian · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.